Company Profile
Jasper Therapeutics Stock Price, News & Catalysts
- Ticker:
- JSPR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.60 USD (+3.10%)
Close
Last updated: October 1, 2026
15.4M USD
Market cap
Why the stock is moving
As of Oct 1, 2026, JSPR closed up 3.10% at $0.5980. No new same-company headline was identified in the current news window.
Company overview
Immune-Mediated Disease Company
Jasper Therapeutics is developing therapies for immune-mediated diseases following its combination with Kira Pharmaceuticals. The expanded portfolio includes programs targeting complement biology, pathogenic immune cells, and mast-cell-driven disorders.
KP-104 Dual Complement Inhibitor
KP-104, or vensobafusp alfa, is a bifunctional molecule designed to inhibit both the alternative and terminal complement pathways. It is Phase 2/3-ready in paroxysmal nocturnal hemoglobinuria and is also being evaluated in a Phase 2 basket study across rare complement-mediated renal diseases.
Briquilimab
Briquilimab is an anti-KIT monoclonal antibody designed to deplete mast cells and hematopoietic stem cells. Jasper is developing the candidate for mast-cell-driven diseases, including chronic urticarias and allergic asthma, and as a conditioning agent for stem-cell transplantation.
KP-701
KP-701 is a dual-acting CD79B and CD32B antibody intended to suppress pathogenic B-cell signaling in autoantibody-mediated disorders. The program is advancing through preclinical development toward an initial clinical application.
Future catalysts
- Stage 1 interim data from the Phase 2 KP-104 renal-disease basket study in Q4 2026.
- Announcement of the briquilimab regulatory path following planned pre-BLA engagement in Q1 2027.
- CTA or IND submission for KP-701 in Q1 2027.
- FDA end-of-Phase 2 meeting and announcement of next development steps for KP-104 in PNH in the first half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Jasper Therapeutics (JSPR)?
Jasper Therapeutics (JSPR) most recently closed at 0.60 USD, a +3.10% move versus the previous session.
What is the market cap of Jasper Therapeutics (JSPR)?
Jasper Therapeutics currently has a market capitalization of 15.4M USD on BioPharmSignal.
What does Jasper Therapeutics do?
Immune-Mediated Disease Company Jasper Therapeutics is developing therapies for immune-mediated diseases following its combination with Kira Pharmaceuticals. The expanded portfolio includes programs targeting complement biology, pathogenic immune cells, and mast-cell-driven disorders. KP-104 Dual Complement Inhibitor KP-104, or vensobafusp alfa, is a...
On which exchange is JSPR stock listed?
Jasper Therapeutics (JSPR) is associated with NASDAQ, United States, Biopharma.
What is KP-104?
Stage 1 interim data from the Phase 2 KP-104 renal-disease basket study in Q4 2026.
Which conditions is Jasper Therapeutics targeting with KP-104?
Stage 1 interim data from the Phase 2 KP-104 renal-disease basket study in Q4 2026.
How does Jasper Therapeutics describe recent progress with KP-104?
Stage 1 interim data from the Phase 2 KP-104 renal-disease basket study in Q4 2026.
What is KP-701?
KP-701 KP-701 is a dual-acting CD79B and CD32B antibody intended to suppress pathogenic B-cell signaling in autoantibody-mediated disorders.